Anti-Human CD64 (FCGR1) – Purified in vivo PLATINUM™ Functional Grade

Anti-Human CD64 (FCGR1) – Purified in vivo PLATINUM™ Functional Grade

Product No.: I-2015

- -
- -
Clone
10.1
Target
CD64
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
FcγRI, FcR I, Fc Gamma Receptor Ia, Fc-Gamma RIA
Isotype
Mouse IgG1 κ
Applications
B
,
FA
,
FC
,
IHC FF
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
Rheumatoid synovial fluid cells and fibronectin purified human monocytes.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this CD64 antibody, clone 10.1, for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ?
B
IHC FF
FA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 10.1 recognizes the alpha subunit of human FCGR1.
Background
FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNγ and G-CSF1. FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG42, resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation1,3. CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis4. In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages5.
Antigen Distribution
FCGR1 is expressed on monocytes, macrophages, dendritic cells (DCs), and activated granulocytes.
Ligand/Receptor
IgG receptor
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

The clone 10.1 is typically used to target CD64 (FcγRI) in human cells, which is involved in innate immunity. However, in the context of mice, it is primarily utilized to study human immune responses in humanized mouse models. While the clone 10.1 is not directly used in mice since it targets human CD64, humanized mouse models are designed to express human immune components, allowing researchers to study human immune responses in vivo. Common applications include:

  1. Immunological Research: Humanized mouse models with the clone 10.1 can be used to study monocyte and macrophage functions, as well as to phenotype immune cells in both research and clinical samples. However, these models would require modifications to express human CD64 or incorporate human immune cells.

  2. Pharmacological Studies: The development of mouse models that express human Fcγ receptors (like the one described in PNAS) allows for the testing of human monoclonal antibodies in a more relevant in vivo setting. Although clone 10.1 is not used in these mice directly, the principle of using humanized models applies.

  3. Cancer and Disease Models: Humanized mouse models can be used to study cancer treatments, including the use of antibodies that target specific human antigens, thereby enabling more accurate preclinical testing of therapies.

For specific applications of clone 10.1 itself, it is primarily used in flow cytometry and other immunological studies in human or humanized contexts rather than in standard mouse models. However, the concept of using humanized models provides a framework for studying human immune interactions in mice.

In summary, while clone 10.1 is not directly applied in mice, it highlights the importance of using humanized models for studying human immune responses in vivo.

Clone 10.1 (anti-CD64) is most commonly used in conjunction with antibodies against other immune cell markers to analyze and phenotype monocyte and macrophage populations in immunological studies.

Key antibodies and proteins frequently used with 10.1 include:

  • CD14: A marker for monocytes/macrophages, often used to distinguish these cells from other leukocytes.
  • CD16: Helps further characterize monocyte subsets (classical, intermediate, non-classical) and NK cells.
  • HLA-DR: Indicates MHC class II expression, useful for assessing activation states of myeloid cells.
  • CD45: A pan-leukocyte marker for identifying total leukocyte populations.
  • CD11b: An integrin associated with monocytes, macrophages, granulocytes, and NK cells, helpful for myeloid cell identification.
  • CD11c: Expressed on monocytes, macrophages, and dendritic cells, included for finer myeloid subset analysis.

These antibodies are typically used in multiparameter flow cytometry panels or immunophenotyping assays to comprehensively define myeloid cell populations, distinguish cell subsets, and assess activation or differentiation states.

Other applications for 10.1 in the literature, occasionally combined with additional proteins or antibodies, include:

  • Blocking of human IgG3 and murine IgG2a binding to FcγRI, particularly in Fc receptor function studies.
  • Immunohistochemistry on tissue sections, where macrophage and monocyte markers may be co-stained to study tissue localization.

In summary, 10.1 is almost always used alongside other lineage or activation markers—especially CD14, CD16, HLA-DR, CD45, CD11b, and CD11c—to provide a comprehensive analysis of human myeloid cell populations in research contexts.

Clone 10.1 is often mentioned in scientific literature in relation to its use as a monoclonal antibody recognizing human CD64 (FcγRI), a receptor expressed on monocytes/macrophages, dendritic cells, and activated granulocytes. While specific citations related to clone 10.1's findings are not detailed in the provided search results, here are key points about CD64 and the implications of clone 10.1:

  1. Recognition of CD64: Clone 10.1 specifically binds to the extracellular epitope of CD64, which is crucial for studying immune responses and cell interactions involving IgG antibodies.

  2. Applications in Immunology: The antibody is commonly used to identify and characterize monocyte and macrophage populations, aiding in understanding their roles in immune diseases and responses.

  3. Research and Diagnostic Use: Clone 10.1 is used in research settings for its specificity and affinity towards CD64, but it is not intended for diagnostic procedures.

Given the lack of detailed citations about specific findings from clone 10.1 in the provided results, these points summarize the general application and significance of clone 10.1 in scientific research. For specific findings or studies, additional literature review would be necessary.

While the specific dosing regimen for clone 10.1 (Anti-Human CD64) in different mouse models is not detailed in the search results, dosing regimens for antibodies like clone 10.1 can vary significantly based on the mouse model used, the experimental objective, and the type of antibody. Typically, dosing regimens for antibodies in mouse models are determined by factors such as the target antigen, the desired immune response, and the specific application of the antibody.

For general guidance, dosing regimens for antibodies in mouse models often involve intraperitoneal or intravenous injections, with dosages ranging from 100 to 500 μg per mouse, depending on the antibody's target and the study's objectives. The frequency of dosing can vary from every 2-3 days to once a week, also depending on the study's requirements.

Since clone 10.1 targets human CD64, it might be used in models where human immune cells are engrafted, such as in humanized mouse models used for studying human immune responses. In these cases, the dosing regimen would need to be tailored specifically to the model's characteristics and the experimental goals.

To determine the optimal dosing regimen for clone 10.1 in a specific mouse model, it would be necessary to consult specific studies using this antibody or to conduct pilot studies to establish the most effective dosing strategy.

References & Citations

1. Hulett MD & Hogarth PM. (1998) Mol Immunol. 35(14-15):989-96
2. M. Daëron., et al. (2009) Blood. 113: 3716–3725
3. Alter G., et al. (2011) Epub. 415(2):160-7
4. Barth S., et al. (2017) Biomedicines. 5(3):56
5. Keler T., et al. (1998) Clin Cancer Res. 4(9):2237-43
B
FA
Flow Cytometry
IHC FF
in vivo Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.